Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL Behring has announced data from a study that demonstrated its new liquid immune globulin intravenous 10% product, Privigen, is well-tolerated in patients with primary immune deficiencies.
Subscribe to our email newsletter
The extension study was aimed to assess the tolerability and safety of Privigen, when administered at infusion rates higher than those of the pivotal study (12mg/kg/min, as opposed to 8mg/kg/min). Results showed that Privigen is well-tolerated at high infusion rates with no temporally associated adverse events requiring an infusion rate reduction or termination during the study. This higher infusion rate may translate into less time spent in the hospitals for patients.
The pivotal study aimed to assess the safety and efficacy in patients with primary immune deficiencies (PI). Privigen met all pre-defined efficacy and safety endpoints.